Aquagenic wrinkling of the palms (aquagenic acrokeratoderma)
Aquagenic wrinkling of the palms (AWP)
(also, aquagenic acrokeratoderma)
Also known as:
Aquagenic palmar wrinkling
(Acquired) aquagenic palmoplantar keratoderma
(Acquired) aquagenic syringeal acrokeratoderma
Acquired aquagenic papulotranslucent acrokeratoderma
Idiopathic aquagenic wrinkling of the palms
Instant aquagenic wrinkling of the palms
Transient aquagenic palmar hyperwrinkling
Transient reactive papulotranslucent acrokeratoderma
Are You Confident of the Diagnosis?
What to be alert for in the history
Patients affected with aquagenic wrinkling of the palms (AWP) complain that upon exposure to water, they note reddening of the skin of the palms, and eventually notice a whitening and thickening of the palms resembling waterlogging. Patients may notice the sensation of burning, stinging, or tingling localized to the palms.
Characteristic findings on physical examination
Characteristic findings include white translucent papules that coalesce into plaques on the palms and palmar aspects of the fingers, especially the fingertips (
Aquagenic wrinkling of the palms in a patient with cystic fibrosis. Note the accentuation at the base of the fingers and on the area around the thenar eminence. (Courtesy of Albert Yan, MD and the Section of Pediatric Dermatology at the Children’s Hospital of Philadelphia.)
The condition manifests in early childhood, and improves with age. Rarely, findings can be seen involving the feet, but the palms are the predominant site of involvement.
Expected results of diagnostic studies
Biopsy in some patients has revealed compact orthokeratosis, acanthosis, and dilatation of intracorneal eccrine sweat ducts (hence the suggestion of aquagenic syringeal acrokeratoderma as a name for this condition by some authors).
Differential diagnosis includes other water-induced phenomena such as aquagenic urticaria. However, aquagenic urticaria tends to be more generalized involving areas of contact, rather than being localized to the palms.
Who is at Risk for Developing this Disease?
The condition was first described in 1974 as “aquagenic wrinkling of the palms” among a group of children with cystic fibrosis (CF). A strong association with CF has subsequently been documented. In one series, 90% of pediatric patients with CF have evidence of discernible AWP. However, in an adult population with CF, the prevalence of CF was only about 41%.
A small subset of children with AWP have no identifiable mutations in the cystic fibrosis gene, cystic fibrosis transmembrane conductance regulator (CFTR). In these children, the condition appears to start during preadolescence or adolescence, to favor girls over boys, and to remit at a younger age.
Aquagenically induced wrinkling of the palms can also be induced by medications (selective cox-2 inhibitors, ACE inhibitors, angiotensin-receptor blockers, and nonsteroidal antiinflammatory drugs [NSAIDs]). This may be related to alterations in sweat electrolytes caused by these agents.
AWP has been reported in patients with marasmus. Patients with marasmus may have elevated sweat electrolytes, which may predispose to AWP.
What is the Cause of the Disease?
The etiology and pathophysiology remain incompletely understood at this time, but several hypotheses exist to help explain why this phenomenon occurs:
The increased sweat salt concentration may increase the osmotic water shift across the stratum corneum
Eccrine duct wall weakness may produce dilatation of eccrine ducts
Increased expression of aquaporins have been identified in some patients with AWP. Since CFTR is involved with aquaporin expression in various epithelia, mutations in CFTR may cause alterations in aquaporins predisposing those with CF to develop AWP.
Of note, the observation that this phenomenon does not occur in concert with exposure to salt water suggests that an osmotic gradient must be present in order for water transfer to occur.
Systemic Implications and Complications
The phenomenon of aquagenic wrinkling of the palms is strongly associated with cystic fibrosis. It is suspected that those heterozygous for mutations in CFTR may have an increased predisposition for AWP.A subset of patients also report associated palmar hyperhidrosis in association with AWP.
Not all patients with AWP, however, have identifiable mutations in CF, although it appears that the majority of patients with AWP have been reported to have CF.
Treatment options include:
Active nonintervention for mild cases
Hydrophobic and hydrophilic ointments or barrier creams
Aluminum chloride hexahydrate 20% solution (Drysol)
A small number of cases have been reported to have been successfully treated with botulinum toxin injections
Optimal Therapeutic Approach for Aquagenic Wrinkling of the Palms
Most patients with mild AWP do not require therapy, and the condition improves over time, abating often during adolescence or young adulthood.
Occlusive emollients prior to immersion in water may reduce the severity of the condition. Petrolatum or other hydrophilic ointments are preferred.
Aluminum chloride hexahydrate 20% applied once or twice daily may help reduce the severity of AWP.
Discontinue any drugs that may contribute to sweat electrolyte imbalances as noted above: selective cox-2 inhibitors, ACE inhibitors, angiotensin-receptor blockers, and NSAIDS. Correct nutritional deficiencies, in rare cases of marasmus-associated AWP.
Patients identified as having AWP should be screened for CF by sweat chloride testing. If the testing is in the equivocal range (a finding that is common among heterozygous carriers), screening for CFTR mutations should be considered to help with appropriate genetic counseling.
Unusual Clinical Scenarios to Consider in Patient Management
Aquagenically-induced wrinkling of the palms can also be induced by medications (selective cox-2 inhibitors, ACE inhibitors, angiotensin-receptor blockers, and NSAIDS. Discontinuation of these medications in those taking them may also reduce the severity of AWP.
What is the Evidence?
Tolland, JP, Boyl, J, Hall, V, McKenna, KE, Elborn, JS. "Aquagenic wrinkling of the palms in an adult cystic fibrosis population". Dermatology. vol. 221. 2010. pp. 326-30.(The prevalence of AWP among adults with CF is about 41%.)
Garcon-Michel, N, Roguedas-Contios, AM, Rault, G, LeBihan, J, Ramel, S, Revert, K. "Frequency of aquagenic palmoplantar keratoderma in cystic fibrosis: a new sign of cystic fibrosis?". Br J Dermatol.. vol. 163. 2010 Jul. pp. 162-6.(The prevalence of AWP among adults with CF is about 41%.)
Gild, R, Clay, CD, Morey, S. "Aquagenic wrinkling of the palms in cystic fibrosis and the cystic fibrosis carrier state: a case-control study". Br J Dermatol. vol. 163. 2010 Nov. pp. 1082-4.(AWP is associated with both CF and CF carrier states.)
Berk, DR, Ciliberto, JM, Sweet, SC, Ferkol, TW, Bayliss, SJ. "Aquagenic wrinkling of the palms in cystic fibrosis: comparison with controls and genotype-phenotype correlations". Arch Dermatol. vol. 145. 2009 Nov. pp. 1296-9.(Highlights association of deltaF508 gene mutations with AWP.)
Kabashim, K, Shimauchi, T, Kobayashi, M, Fukumachi, S, Kawakami, C, Ogata, M, Kabashima, R, Mori, T, Ota, T, Fukushima, S, Hara-Chikuma, M, Tokura, Y. "Aberrant aquaporin 5 expression in the sweat gland in aquagenic wrinkling of the palms". J Am Acad Dermatol. vol. 59. 2008 Aug. pp. S28-32.(Increased aquaporin expression among those with AWP.)
Katz, KA, Yan, AC, Turner, ML. "Aquagenic wrinkling of the palms in patients with cystic fibrosis homozygous for the delta F508 CFTR mutation". Arch Dermatol. vol. 141. 2005 May. pp. 621-4.(First to highlight association of delta F508 mutation with AWP.)
MacCormack, MA, Wiss, K, Malhotra, R. "Aquagenic syringeal acrokeratoderma: report of two teenage cases". J Am Acad Dermatol. vol. 45. 2001 Jul. pp. 124-6.(First to highlight the histopathologic findings of eccrine duct prominence and dilated eccrine ostia.)
Yan, AC, Aasi, SZ, Alms, WJ, James, WD, Heymann, WR, Paller, AS, Honig, PJ. "Aquagenic palmoplantar keratoderma". J Am Acad Dermatol. vol. 44. 2001 Apr. pp. 696-9.(Highlighted the hand-in-the-bucket sign, and use of aluminum chloride hexahydrate solution as a topical treatment for AWP.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT
- Additional FDA Approval for Olaparib Tablets in Ovarian Cancer
- Besponsa Approved for B-cell Acute Lymphoblastic Leukemia
- Calcium and Cancer
- Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma